In The Lancet Neurology, Frisoni and colleagues present a thoughtful and topical Insight, but I disagree with their recommendations. They point out that, although the National Institute on Aging–Alzheimer's Association (NIA-AA) research framework recommends defining the disease biologically (by abnormal biomarkers denoting both amyloid and tau deposits) independent from symptomatic presentation, most in the lay community understand the term Alzheimer's disease to mean a progressive cognitive impairment that leads to dementia. This disparity creates a conceptual disconnect between the lay and scientific communities. The solution recommended by Frisoni and colleagues is that the term Alzheimer's disease be reserved for symptomatic individuals.

中文翻译：

---

临床前阿尔茨海默氏病：有效概念。

在《柳叶刀神经病学》中，弗里索尼和同事们提出了一个具有思想性和主题性的见解，但我不同意他们的建议。他们指出，尽管美国老年痴呆症协会（NIA-AA）的研究框架建议从生物学上定义疾病（通过异常的生物标志物表示淀粉样蛋白和tau沉积物），而与症状表现无关，但大多数外行社区都理解该术语阿尔茨海默氏病是指导致痴呆的进行性认知障碍。这种差异在外行人和科学界之间造成了概念上的脱节。Frisoni及其同事推荐的解决方案是，阿尔茨海默氏病一词仅用于有症状的个体。